REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results